Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin

Sergio Anastasi, Gianluca Sala, Chen Huiping, Elisabetta Caprini, Giandomenico Russo, Stefano Iacovelli, Fabiana Lucini, Sigurdur Ingvarsson, Oreste Segatto

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

An emerging paradigm holds that loss of negative signalling to receptor tyrosine kinases (RTKs) is permissive for their oncogenic activity. Herein, we have addressed tumor suppression by RALT/MIG-6, a transcriptionally controlled feedback inhibitor of ErbB RTKs, in breast cancer cells. Knockdown of RALT expression by RNAi enhanced the EGF-dependent proliferation of normal breast epithelial cells, indicating that loss of RALT signalling in breast epithelium may represent an advantageous condition during ErbB-driven tumorigenesis. Although mutational inactivation of the RALT gene was not detected in human breast carcinomas, RALT mRNA and protein expression was strongly and selectively reduced in ERBB2-amplified breast cancer cell lines. Reconstitution of RALT expression in ERBB2-amplified SKBr-3 and BT474 cells inhibited ErbB-2-dependent mitogenic signalling and counteracted the ability of ErbB ligands to promote resistance to the ErbB-2-targeting drug Herceptin. Thus, loss of RALT expression cooperates with ERBB2 gene amplification to drive full oncogenic signalling by the ErbB-2 receptor. Moreover, loss of RALT signalling may adversely affect tumor responses to ErbB-2-targeting agents.

Original languageEnglish
Pages (from-to)4540-4548
Number of pages9
JournalOncogene
Volume24
Issue number28
DOIs
Publication statusPublished - Jun 30 2005

Fingerprint

Breast Neoplasms
Breast
ErbB-2 Receptor
Gene Amplification
Receptor Protein-Tyrosine Kinases
Gene Silencing
Drug Delivery Systems
RNA Interference
Epidermal Growth Factor
Protein-Tyrosine Kinases
Neoplasms
Carcinogenesis
Epithelium
Epithelial Cells
Ligands
Cell Line
Messenger RNA
Trastuzumab
Proteins
ErbB Receptors

Keywords

  • Breast cancer
  • ErbB-2
  • Herceptin
  • MIG-6
  • RALT
  • Targeted therapies

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. / Anastasi, Sergio; Sala, Gianluca; Huiping, Chen; Caprini, Elisabetta; Russo, Giandomenico; Iacovelli, Stefano; Lucini, Fabiana; Ingvarsson, Sigurdur; Segatto, Oreste.

In: Oncogene, Vol. 24, No. 28, 30.06.2005, p. 4540-4548.

Research output: Contribution to journalArticle

Anastasi, Sergio ; Sala, Gianluca ; Huiping, Chen ; Caprini, Elisabetta ; Russo, Giandomenico ; Iacovelli, Stefano ; Lucini, Fabiana ; Ingvarsson, Sigurdur ; Segatto, Oreste. / Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. In: Oncogene. 2005 ; Vol. 24, No. 28. pp. 4540-4548.
@article{c00683f5ec774627af90276bc384db61,
title = "Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin",
abstract = "An emerging paradigm holds that loss of negative signalling to receptor tyrosine kinases (RTKs) is permissive for their oncogenic activity. Herein, we have addressed tumor suppression by RALT/MIG-6, a transcriptionally controlled feedback inhibitor of ErbB RTKs, in breast cancer cells. Knockdown of RALT expression by RNAi enhanced the EGF-dependent proliferation of normal breast epithelial cells, indicating that loss of RALT signalling in breast epithelium may represent an advantageous condition during ErbB-driven tumorigenesis. Although mutational inactivation of the RALT gene was not detected in human breast carcinomas, RALT mRNA and protein expression was strongly and selectively reduced in ERBB2-amplified breast cancer cell lines. Reconstitution of RALT expression in ERBB2-amplified SKBr-3 and BT474 cells inhibited ErbB-2-dependent mitogenic signalling and counteracted the ability of ErbB ligands to promote resistance to the ErbB-2-targeting drug Herceptin. Thus, loss of RALT expression cooperates with ERBB2 gene amplification to drive full oncogenic signalling by the ErbB-2 receptor. Moreover, loss of RALT signalling may adversely affect tumor responses to ErbB-2-targeting agents.",
keywords = "Breast cancer, ErbB-2, Herceptin, MIG-6, RALT, Targeted therapies",
author = "Sergio Anastasi and Gianluca Sala and Chen Huiping and Elisabetta Caprini and Giandomenico Russo and Stefano Iacovelli and Fabiana Lucini and Sigurdur Ingvarsson and Oreste Segatto",
year = "2005",
month = "6",
day = "30",
doi = "10.1038/sj.onc.1208658",
language = "English",
volume = "24",
pages = "4540--4548",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "28",

}

TY - JOUR

T1 - Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin

AU - Anastasi, Sergio

AU - Sala, Gianluca

AU - Huiping, Chen

AU - Caprini, Elisabetta

AU - Russo, Giandomenico

AU - Iacovelli, Stefano

AU - Lucini, Fabiana

AU - Ingvarsson, Sigurdur

AU - Segatto, Oreste

PY - 2005/6/30

Y1 - 2005/6/30

N2 - An emerging paradigm holds that loss of negative signalling to receptor tyrosine kinases (RTKs) is permissive for their oncogenic activity. Herein, we have addressed tumor suppression by RALT/MIG-6, a transcriptionally controlled feedback inhibitor of ErbB RTKs, in breast cancer cells. Knockdown of RALT expression by RNAi enhanced the EGF-dependent proliferation of normal breast epithelial cells, indicating that loss of RALT signalling in breast epithelium may represent an advantageous condition during ErbB-driven tumorigenesis. Although mutational inactivation of the RALT gene was not detected in human breast carcinomas, RALT mRNA and protein expression was strongly and selectively reduced in ERBB2-amplified breast cancer cell lines. Reconstitution of RALT expression in ERBB2-amplified SKBr-3 and BT474 cells inhibited ErbB-2-dependent mitogenic signalling and counteracted the ability of ErbB ligands to promote resistance to the ErbB-2-targeting drug Herceptin. Thus, loss of RALT expression cooperates with ERBB2 gene amplification to drive full oncogenic signalling by the ErbB-2 receptor. Moreover, loss of RALT signalling may adversely affect tumor responses to ErbB-2-targeting agents.

AB - An emerging paradigm holds that loss of negative signalling to receptor tyrosine kinases (RTKs) is permissive for their oncogenic activity. Herein, we have addressed tumor suppression by RALT/MIG-6, a transcriptionally controlled feedback inhibitor of ErbB RTKs, in breast cancer cells. Knockdown of RALT expression by RNAi enhanced the EGF-dependent proliferation of normal breast epithelial cells, indicating that loss of RALT signalling in breast epithelium may represent an advantageous condition during ErbB-driven tumorigenesis. Although mutational inactivation of the RALT gene was not detected in human breast carcinomas, RALT mRNA and protein expression was strongly and selectively reduced in ERBB2-amplified breast cancer cell lines. Reconstitution of RALT expression in ERBB2-amplified SKBr-3 and BT474 cells inhibited ErbB-2-dependent mitogenic signalling and counteracted the ability of ErbB ligands to promote resistance to the ErbB-2-targeting drug Herceptin. Thus, loss of RALT expression cooperates with ERBB2 gene amplification to drive full oncogenic signalling by the ErbB-2 receptor. Moreover, loss of RALT signalling may adversely affect tumor responses to ErbB-2-targeting agents.

KW - Breast cancer

KW - ErbB-2

KW - Herceptin

KW - MIG-6

KW - RALT

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=22744445536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22744445536&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1208658

DO - 10.1038/sj.onc.1208658

M3 - Article

VL - 24

SP - 4540

EP - 4548

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 28

ER -